Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03603743
Other study ID # 2-15-12
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 7, 2015
Est. completion date October 13, 2017

Study information

Verified date July 2018
Source Cardiovascular and Pulmonary Rehabilitation Center of Saint Orens
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose: Exaggerated sympathetic nervous system (SNS) activity associated with low heart rate variability (HRV) is considered as a trigger of cardiac arrhythmias and sudden death. Regular exercise training is efficient to improve autonomic balance. In 2013, the investigators published that a single session of an optimized short-high intensity interval exercise with passive recovery (HIIT) protocol was efficient in chronic heart failure (CHF) patients for enhancing vagal tone and to decrease arrhythmias in the 24-h post exercise period when compared to a single session of moderate intensity continuous exercise (MICT). Nevertheless the effects of HIIT training performed on several weeks have never yet been studied on the parameters described by Coumel's triangle (the arrhythmogenic substrate, the trigger factor as premature ventricular contraction and the modulation factors of which the most common is the autonomic nervous system). The aim of this study was to verify the superiority of HIIT to enhance parasympathetic activity, cardiorespiratory fitness and cardiac function when compared to MICT in a short and intense cardiac rehabilitation program.


Description:

Before and after the Rehabilitation Program (RP), all patients underwent a 24-hour ECG recording, an echocardiography, a cardiopulmonary exercise test.

The RP consisted of 2 types of exercise training according to the randomization:

1. a short-high intensity interval exercise with passive recovery

2. a classical moderate and continuous exercise training at 60% of peak power output

The RP lasted 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date October 13, 2017
Est. primary completion date October 13, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- stable chronic heart failure with NYHA functional class from I to III

- stable left ventricular ejection fraction (LVEF) < 45% over at least 6 months

- stable optimal medical therapy including a beta-blocker and an angiotensin-converting enzyme inhibitor or angiotensin receptor blockers for at least 6 weeks

- ability to perform a maximal cardiopulmonary exercise test

- admitted to the Rehabilitation Centre for a comprehensive Cardiovascular Rehabilitation Program

Exclusion Criteria:

- any relative or absolute contraindications to exercise training according to current recommendations

- fixed-rate pacemaker with heart rate limits set lower than exercise training target

- major cardiovascular event or procedure within the 3 months preceding enrolment

- chronic atrial fibrillation

- heart failure secondary to significant uncorrected primary valve disease (except for mitral regurgitation secondary to left ventricular dysfunction)

- heart failure secondary to congenital heart disease or obstructive cardiomyopathy.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
exercise training in heart failure with HIIT
to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
Cardiovascular and Pulmonary Rehabilitation Center of Saint Orens Clinique Pasteur, Institut National de la Santé Et de la Recherche Médicale, France, University Hospital, Toulouse

Outcome

Type Measure Description Time frame Safety issue
Primary High Frequency power in normalized units (HFnu%) based on Heart Rate Variability, the power spectral density of the HF (0.15-0.40 Hz, ms2.Hz-1) bands were calculated. Change from baseline through study completion, an average of 4 weeks (measured during the night period for stationary signal)
Secondary maximal oxygen consumption (VO2peak ml.min.kg) VO2 at peak exercise was measured with Cardiopulmonary Exercise Test. Change from baseline through study completion, an average of 4 weeks
Secondary First ventilatory threshold (VT1) (ml.min.kg) VO2 at VT1 was measured with Cardiopulmonary Exercise Test. Change from baseline through study completion, an average of 4 weeks
Secondary Heart Rate Recovery (beats per minute, bpm) Heart Rate Recovery (with passive recovery) at 1, 2 and 3 minutes after peak exercise (in beats per minute, bpm) Change from baseline through study completion, an average of 4 weeks
Secondary Left Ventricular Ejection Fraction (LVEF, %) LV volumes and ejection fraction were calculated from apical recordings by modified biplane Simpson's method. Change from baseline through study completion, an average of 4 weeks
Secondary premature ventricular contraction, (n/24h) Ectopic ventricular beats were classified as isolated premature contractions, bigeminy, and salves. Change from baseline through study completion, an average of 4 weeks
Secondary NT-pro-BNP, (ng/L) blood sample analysis Change from baseline through study completion, an average of 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03597646 - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure N/A
Terminated NCT04065997 - Apogee International
Withdrawn NCT03675113 - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure N/A
Completed NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study Phase 4
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Completed NCT02268500 - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT) Phase 4
Completed NCT02247245 - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients. N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT01919918 - Muscle Afferent Feedback Effects in Patients With Heart Failure Phase 1
Not yet recruiting NCT01669395 - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial N/A
Completed NCT00984529 - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia N/A
Recruiting NCT00863421 - Sleep Disordered Breathing in Patients With Chronic Heart Failure N/A
Completed NCT02840565 - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 Phase 1
Completed NCT02441218 - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study Phase 3
Completed NCT00149409 - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure Phase 2/Phase 3
Terminated NCT05532046 - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) Phase 1
Recruiting NCT04984928 - Readmission Risk of Patients With Heart Failure.
Completed NCT02814097 - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05560737 - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I